Research Article

Clinical Characteristics of Peripheral Neuropathy in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Single-Center Study in China

Table 3

Comparison of two subtypes of peripheral neuropathy in EGPA.

CharacteristicsMultiple peripheral neuropathy()Mononeuritis multiplex() value

Demographics
Age (year, x ± S)49±12.945±12.80.404
Gender (male/female, n)17/1610/80.782
Time from allergy to EGPA diagnosis (month), median (IQR)24(0, 82.5)22(4.8, 150)0.593
Disease duration (month), median (IQR)6(2,18.5)10.5(2.8, 19.3)0.453
Time from initial symptoms to EGPA diagnosis (month), median (IQR)12(0,48)15(0, 51)0.96
Clinical manifestation[n (%)]
Weight loss17(51.5)8(44.4)0.629
Fever17(51.5)7(38.9)0.388
Arthritis or joint pain9(27.3)3(16.7)0.393
Myalgia7(21.2)7(38.9)0.176
Allergic rhinitis9(27.3)6(33.3)0.650
Asthma24(72.7)16(88.9)0.180
Cutaneous vasculitis12(36.4)14(77.8)0.005
Renal involvement7(21.2)9(50.0)0.034
Digestive tract involvement12(36.4)8(44.4)0.572
CNS involvement7(21.2)4(22.2)1.000
Heart involvement14(42.4)6(33.3)0.525
Ear involvement5(15.2)3(16.7)1.000
Sinusitis19(57.6)10(55.6)0.889
MPO-ANCA7(21.2)5(27.8)0.597
PR3-ANCA2(6.1)0(0)0.287
Eos count (×109/L), median (IQR)2.93(0.43,7.42)4.40(2.41,9.45)0.128
Eos%, median (IQR)22.8(9.3,47.8)41.0(22.6,49.8)0.161
Clinical score
BVAS (recent 4 weeks,x±S)17.82 ±5.58721 ±6.8080.078
FFS ≥1 [n (%)]22(66.7)9(50)0.244

PN: peripheral neuropathy; CNS: Central Nervous System; MPO: myeloperoxidase; ANCA: anti-neutrophil cytoplasmic antibody; PR3: protease 3; Eos: eosinophil; BVAS: Birmingham Vasculitis Activity Score; FFS: five factor score; .